Skip to main content

Jeffrey Melson Clarke

Associate Professor of Medicine
Medicine, Medical Oncology
Dept of Medicine, BOX_31379 Med Ctr, Durham, NC 27710

Selected Grants


C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer

Clinical TrialPrincipal Investigator · Awarded by AbelZeta Inc. · 2024 - 2029

Amgen 20190341

Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2028

GT103_HCRN_NSCLC

Clinical TrialPrincipal Investigator · Awarded by Hoosier Cancer Research Network, Inc · 2023 - 2027

C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer

Clinical TrialPrincipal Investigator · Awarded by AbelZeta Inc. · 2024 - 2029

Amgen 20190341

Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2028

GT103_HCRN_NSCLC

Clinical TrialPrincipal Investigator · Awarded by Hoosier Cancer Research Network, Inc · 2023 - 2027

Amgen AMG 757 (SCLC)

Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2022 - 2027

Clinical and Therapeutic Implications of the Small Nucleolar RNA Snord67 in Breast Cancer Lymphatic Metastasis

ResearchMentor · Awarded by American Society of Clinical Oncology · 2024 - 2025

A Phase 1b Study Evaluating the Safety and Tolerability, and Efficacy of AMG510 in Combination with Everolimus

Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2022 - 2025

Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

Clinical TrialPrincipal Investigator · Awarded by Grid Therapeutics LLC · 2020 - 2025

A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer

Clinical TrialPrincipal Investigator · Awarded by Array BioPharma Inc · 2019 - 2024

Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable NSCLC

Clinical TrialPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2019 - 2024

Adaptimmune SURPASS

Clinical TrialPrincipal Investigator · Awarded by Adaptimmune Limited · 2019 - 2024

A phase I/IIa study of BMS986148 a Mesothelin directed antibody drug conjugate in subjects with select advanced solid tumors

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2015 - 2023

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Clinical TrialSignificant Contributor · Awarded by National Institutes of Health · 2014 - 2023

Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer

ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2022

CBMG NSCLC Tumor Specimens for TIL Cell Therapy

ResearchPrincipal Investigator · Awarded by Cellular Biomedicine Group, Inc. · 2020 - 2022

Cell-Free DNA for Diagnosis of Malignancy, Genetic Mutations and Prognosis in Lung Cancer Related Pleural Effusions

ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2022

Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2020 - 2021

Adaptimmune MAGE A-4

Clinical TrialPrincipal Investigator · Awarded by Adaptimmune Limited · 2018 - 2020

Adaptimmune MAGE

Clinical TrialPrincipal Investigator · Awarded by Adaptimmune Limited · 2018 - 2020

First-in-human dose escalation of TEW-7197 monotherapy in subjects with advanced stage solid tumors

Clinical TrialPrincipal Investigator · Awarded by MedPacto, Inc · 2014 - 2020

Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer

ResearchPrincipal Investigator · Awarded by V Foundation for Cancer Research · 2016 - 2018

Evaluation of Tumor Infiltrating Lymphocytes in Resected Non Small Cell Lung Cancer

FellowshipPrincipal Investigator · Awarded by Lung Cancer Initiative of North Carolina · 2015 - 2018

Blood-based Biomarker Profiling for TEW-7197

ResearchPrincipal Investigator · Awarded by MedPacto, Inc · 2016 - 2018

External Relationships


  • Amgen, Inc.
  • AstraZeneca
  • Bristol-Myers Squibb (BMS)
  • Corbus
  • Dava Oncology
  • Amgen, Inc.
  • AstraZeneca
  • Bristol-Myers Squibb (BMS)
  • Corbus
  • Dava Oncology
  • G1 Therapeutics, Inc.
  • Jannsen Pharmaceuticals
  • MD Outlook
  • MJH Life Sciences
  • Merck & Co. USA (not assoc'd with Merck KGaA)
  • Sanofi

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.